EdgarLookup

APPLIED ENERGETICS, INC. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that APPLIED ENERGETICS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-3221.1%
Profit Margin
Net income ÷ revenue
-164.1%
Return on Assets
Net income ÷ assets
0.2x
Debt-to-Equity
Total liabilities ÷ equity
-81%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $461.7K Mar 30, 2026
FY2025 Dec 31, 2024 $2.43M Mar 30, 2026
FY2024 Dec 31, 2023 $2.63M Mar 28, 2025
FY2023 Dec 31, 2022 $1.31M Mar 26, 2024

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2013 Dec 31, 2013 $1.9K Apr 14, 2014
FY2013 Sep 30, 2013 $2.1K Apr 14, 2014
FY2013 Jun 30, 2013 $4.3K Apr 14, 2014
FY2013 Mar 31, 2013 $34.5K Apr 14, 2014
FY2012 Dec 31, 2012 $119.9K Mar 29, 2013
FY2012 Sep 30, 2012 $312.0K Mar 29, 2013
FY2012 Jun 30, 2012 $504.3K Mar 29, 2013
FY2012 Mar 31, 2012 $399.2K Mar 29, 2013
FY2012 Dec 31, 2011 $619.6K Mar 29, 2013
FY2012 Sep 30, 2011 $611.2K Mar 29, 2013

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $249.1K Mar 30, 2026
FY2025 Dec 31, 2024 $946.5K Mar 30, 2026
FY2024 Dec 31, 2023 $1.99M Mar 28, 2025
FY2023 Dec 31, 2022 $1.00M Mar 26, 2024
FY2021 Dec 31, 2020 $22.3K Mar 31, 2022
FY2015 Dec 31, 2015 $0 Apr 1, 2016
FY2015 Dec 31, 2014 $6.0K Apr 1, 2016
FY2013 Dec 31, 2013 $1.9K Apr 14, 2014
FY2013 Sep 30, 2013 $2.1K Apr 14, 2014
FY2013 Jun 30, 2013 ($2.7K) Apr 14, 2014

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($14.87M) Mar 30, 2026
FY2025 Dec 31, 2024 ($9.17M) Mar 30, 2026
FY2024 Dec 31, 2023 ($7.35M) Mar 28, 2025
FY2023 Dec 31, 2022 ($5.77M) Mar 26, 2024
FY2022 Dec 31, 2021 ($5.43M) Mar 30, 2023
FY2021 Dec 31, 2020 ($3.23M) Mar 31, 2022
FY2020 Dec 31, 2019 ($5.56M) Apr 12, 2021
FY2019 Dec 31, 2018 ($3.01M) Apr 3, 2020
FY2018 Dec 31, 2017 ($790.0K) Apr 1, 2019
FY2017 Dec 31, 2016 ($492.6K) Apr 17, 2018

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($14.93M) Mar 30, 2026
FY2025 Dec 31, 2024 ($9.18M) Mar 30, 2026
FY2024 Dec 31, 2023 ($7.40M) Mar 28, 2025
FY2023 Dec 31, 2022 ($5.77M) Mar 26, 2024
FY2022 Dec 31, 2021 ($5.50M) Mar 30, 2023
FY2021 Dec 31, 2020 ($5.24M) Mar 31, 2022
FY2020 Dec 31, 2019 ($5.17M) Apr 12, 2021
FY2019 Dec 31, 2018 ($2.76M) Apr 3, 2020
FY2018 Dec 31, 2017 ($752.3K) Apr 1, 2019
FY2017 Dec 31, 2016 ($495.2K) Apr 17, 2018

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.67M Mar 30, 2026
FY2025 Dec 31, 2024 $239.1K Mar 30, 2026
FY2024 Dec 31, 2023 $233.7K Mar 28, 2025
FY2023 Dec 31, 2022 $320.5K Mar 26, 2024
FY2022 Dec 31, 2021 $281.9K Mar 30, 2023
FY2021 Dec 31, 2020 $266.9K Mar 31, 2022
FY2020 Dec 31, 2019 $335.4K Apr 12, 2021
FY2019 Dec 31, 2018 $190.5K Apr 3, 2020
FY2013 Dec 31, 2012 $157.3K Apr 14, 2014
FY2012 Dec 31, 2011 $1.67M Mar 29, 2013

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($9.24M) Mar 30, 2026
FY2025 Dec 31, 2024 ($5.09M) Mar 30, 2026
FY2024 Dec 31, 2023 ($3.45M) Mar 28, 2025
FY2023 Dec 31, 2022 ($3.93M) Mar 26, 2024
FY2022 Dec 31, 2021 ($3.21M) Mar 30, 2023
FY2021 Dec 31, 2020 ($160.3K) Mar 31, 2022
FY2020 Dec 31, 2019 ($3.25M) Apr 12, 2021
FY2019 Dec 31, 2018 ($1.79M) Apr 3, 2020
FY2018 Dec 31, 2017 ($200.4K) Apr 1, 2019
FY2017 Dec 31, 2016 ($136.2K) Apr 17, 2018

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.23M Mar 30, 2026
FY2025 Dec 31, 2024 $98.8K Mar 30, 2026
FY2024 Dec 31, 2023 $369.3K Mar 28, 2025
FY2023 Dec 31, 2022 $74.2K Mar 26, 2024
FY2022 Dec 31, 2021 $207.4K Mar 30, 2023
FY2020 Dec 31, 2019 $12.4K Apr 12, 2021
FY2013 Dec 31, 2012 $15.1K Apr 14, 2014
FY2012 Dec 31, 2011 $237.2K Mar 29, 2013
FY2011 Dec 31, 2010 $80.7K Mar 29, 2012

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $9.06M Mar 30, 2026
FY2025 Dec 31, 2024 $2.07M Mar 30, 2026
FY2024 Dec 31, 2023 $3.54M Mar 28, 2025
FY2023 Dec 31, 2022 $6.73M Mar 26, 2024
FY2022 Dec 31, 2021 $4.89M Mar 30, 2023
FY2021 Dec 31, 2020 $4.63M Mar 31, 2022
FY2020 Dec 31, 2019 $2.85M Apr 12, 2021
FY2019 Dec 31, 2018 $729.9K Apr 3, 2020
FY2018 Dec 31, 2017 $3.1K Apr 1, 2019
FY2017 Dec 31, 2016 $992 Apr 17, 2018

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.50M Mar 30, 2026
FY2025 Dec 31, 2024 $1.68M Mar 30, 2026
FY2024 Dec 31, 2023 $1.92M Mar 28, 2025
FY2023 Dec 31, 2022 $1.15M Mar 26, 2024
FY2022 Dec 31, 2021 $1.92M Mar 30, 2023
FY2021 Dec 31, 2020 $2.93M Mar 31, 2022
FY2020 Dec 31, 2019 $5.77M Apr 12, 2021
FY2019 Dec 31, 2018 $1.37M Apr 3, 2020
FY2018 Dec 31, 2017 $864.8K Apr 1, 2019
FY2017 Dec 31, 2016 $348.9K Apr 17, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $7.56M Mar 30, 2026
FY2025 Dec 31, 2024 $392.7K Mar 30, 2026
FY2025 Dec 31, 2023 $1.62M Mar 30, 2026
FY2024 Dec 31, 2022 $5.58M Mar 28, 2025
FY2023 Dec 31, 2021 $2.97M Mar 26, 2024
FY2022 Dec 31, 2020 $1.70M Mar 30, 2023
FY2020 Dec 31, 2019 ($2.92M) Apr 12, 2021
FY2020 Dec 31, 2018 ($640.5K) Apr 12, 2021
FY2019 Dec 31, 2017 ($861.8K) Apr 3, 2020
FY2018 Dec 31, 2016 ($347.9K) Apr 1, 2019

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($134.86M) Mar 30, 2026
FY2025 Dec 31, 2024 ($119.99M) Mar 30, 2026
FY2024 Dec 31, 2023 ($110.81M) Mar 28, 2025
FY2023 Dec 31, 2022 ($103.46M) Mar 26, 2024
FY2022 Dec 31, 2021 ($97.69M) Mar 30, 2023
FY2021 Dec 31, 2020 ($92.27M) Mar 31, 2022
FY2020 Dec 31, 2019 ($89.04M) Apr 12, 2021
FY2019 Dec 31, 2018 ($83.48M) Apr 3, 2020
FY2018 Dec 31, 2017 ($80.47M) Apr 1, 2019
FY2017 Dec 31, 2016 ($79.68M) Apr 17, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $6.44M Mar 30, 2026
FY2024 Dec 31, 2024 $164.8K Mar 28, 2025
FY2024 Dec 31, 2023 $1.32M Mar 28, 2025
FY2022 Dec 31, 2022 $5.64M Mar 30, 2023
FY2022 Dec 31, 2021 $3.66M Mar 30, 2023
FY2020 Dec 31, 2020 $3.32M Apr 12, 2021
FY2020 Dec 31, 2019 $88.4K Apr 12, 2021
FY2020 Dec 31, 2018 $178.6K Apr 12, 2021
FY2019 Dec 31, 2017 $2.8K Apr 3, 2020
FY2018 Dec 31, 2016 $680 Apr 1, 2019

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2020 Dec 31, 2020 $1.13M Apr 12, 2021
FY2019 Dec 31, 2019 $1.50M Apr 3, 2020

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 0 Mar 30, 2026
FY2025 Dec 31, 2024 0 Mar 30, 2026
FY2024 Dec 31, 2023 0 Mar 28, 2025
FY2023 Dec 31, 2022 0 Mar 26, 2024
FY2022 Dec 31, 2021 0 Mar 30, 2023
FY2021 Dec 31, 2020 0 Mar 31, 2022

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 0 Mar 30, 2026
FY2025 Dec 31, 2024 0 Mar 30, 2026
FY2024 Dec 31, 2023 0 Mar 28, 2025
FY2023 Dec 31, 2022 0 Mar 26, 2024
FY2022 Dec 31, 2021 0 Mar 30, 2023

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 229.58M Mar 30, 2026
FY2025 Dec 31, 2024 213.86M Mar 30, 2026
FY2024 Dec 31, 2023 211.24M Mar 28, 2025
FY2023 Dec 31, 2022 210.85M Mar 26, 2024
FY2022 Dec 31, 2021 207.56M Mar 30, 2023
FY2021 Dec 31, 2020 190.53M Mar 31, 2022
FY2020 Dec 31, 2019 206.57M Apr 12, 2021
FY2019 Dec 31, 2018 201.70M Apr 3, 2020
FY2018 Dec 31, 2017 157.79M Apr 1, 2019
FY2017 Dec 31, 2016 154.79M Apr 17, 2018